\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes HealthThe European Health and Digital Executivey Agency (HaDEA) has recently published a tentative Calendar of open calls for proposals of the EU4Health Work Programme 2024. It is available here.
Please note that the timing of publication is only indicative and might be subject to change.
Background information: EU4Health aims to pave the way for a stronger, healthier and more resilient Health Union. EU4Health is the largest health programme ever and will invest over €5 billion over 7 years (2021-2027) to improve health in the Union. The Belgian contact point for EU4Health is situated in FPS Public Health. Contact information: Laurence Ballieux; laurence.ballieux@health.fgov.be
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
The European Cybersecurity Competence Centre (ECCC) has opened a call for tenders to set up a European testing infrastructure for post-quantum cryptography (PQC). Open to applicants across the European Economic Area, the contract is worth EUR 25 million and covers IT services including development and support. The submission deadline is 20 Februa... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
